COMPARATIVE IN VITRO ACTIVITY OF SUPIME AGAINST GRAM NEGATIVE CLINICAL ISOLATES

Objective: Present investigation was undertaken to know the prevalence of extended spectrum beta-lactamases (ESBLs) among the collected isolates and to analyse the antibiotic susceptibility patterns of cefepime/sulbactam, cefepime/tazobactam, imipenem/cilastatin and cefepime against these isolates.Methods: A total of 1259 clinical samples were collected from patients suspected of bacterial infection between July 2013 to July 2014. These samples were subjected for bacterial identification. The prevalence of ESBLs among these isolates and antibiotic susceptibility testing were carried out according to the recommendations of Clinical Laboratory Standards Institute (CLSI) guidelines (2013).Results: Out of the samples analyzed, 64.3% (810/1259) samples showed the growth of organisms in the culture medium. Of the 810 organisms, 72.7% (589/810) were ESBL positive. Majority of ESBL producing organisms were obtained from urine (32.2 %) followed by blood (28.5 %), swab (12.7%) and sputum (11.3 %). Pus, Bile and fluid samples samples contributed to 8.1 %, 4.0 %, and 3.0% respectively. The organisms that identified were E. coli (n=255), P. aeruginosa (208), Klebsiella spp. (81), A. baumannii (32), and H. Influenzae (13). Among all drugs tested, cefepime plus sulbactam (Supime) revealed the highest activity against ESBL producing Gram negative organisms. The susceptibility of cefepime plus sulbactam against E. coli, P. aeruginosa, K. pneumoniae, A. baumannii, and H. influenzae was 89.9%, 84.6%, 85%, 90.4% and 100%, respectively which was high compared to cefepime, cefepime plus tazobactam and imipenem plus cilastatin.Conclusion: Overall, the results of the present study strongly advocate the superiority of cefepime/sulbactam over cefepime/tazobactam, imipenem/cilastatin and cefepime and can be of very effective alternative to treat against the deadly multidrug resistant Gram negative bacteria.Â